BiomX announced that it has raised approximately $12 million from investors including the Cystic Fibrosis Foundation to fund a Phase 2b study of its BX004 inhaled phage cocktail for the treatment of P. aeruginosa lung infections in cystic fibrosis patients. In November 2023, BiomX said that it planned to advance BX004 into a Phase 2b/3 trial if it could raise sufficient funds. The company says that it expects to have topline results from the new study in early 2026.
BiomX CEO Jonathan Solomon commented, “Following these offerings, we expect to have sufficient funding to reach substantial inflection points including topline results of our Phase 2b study of BX004 in Q1 2026. . . . Following communication with the FDA we intend to present our plans to analyze real-world evidence and attain endorsement that supports potential future regulatory filings. We anticipate further discussion with the FDA and European Committee for Medicinal Products for Human Use (CHMP) later this year to discuss our proposed plan. To date, the FDA has granted BX004 Fast Track designation and orphan drug designation.”
Read the BiomX press release
